1.32
+0.27(+25.71%)
Currency In USD
| Previous Close | 1.05 |
| Open | 1.06 |
| Day High | 1.42 |
| Day Low | 0.94 |
| 52-Week High | 16.8 |
| 52-Week Low | 0.58 |
| Volume | 9.46M |
| Average Volume | 2.01M |
| Market Cap | 34.21M |
| PE | -0.92 |
| EPS | -1.44 |
| Moving Average 50 Days | 1.44 |
| Moving Average 200 Days | 1.6 |
| Change | 0.27 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $13.5 as of February 05, 2025 at a share price of $1.32. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $13.4 as of February 05, 2025 at a share price of $1.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
GlobeNewswire Inc.
Jan 29, 2025 1:00 PM GMT
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a w
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
GlobeNewswire Inc.
Jan 28, 2025 1:00 PM GMT
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its ending cash
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, ti